



MARKET RELEASE

18 November 2016

Zelda Therapeutics Limited (previously Gleneagle Gold Limited)

PRE-REINSTATEMENT DISCLOSURE

Zelda Therapeutics Limited (“Company”) will be reinstated to Official Quotation as from the commencement of trading on Tuesday 22 November 2016, following the Company’s re-compliance with listing rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules.

The following information is released as pre-reinstatement disclosure.

1. Appendix 1A and Information Form and Checklist.
2. Distribution schedule.
3. Constitution.
4. A statement confirming:
 - a. The capital structure of the Company.
 - b. The number of securities subject to escrow and the escrow period applied to those securities.
5. Top 20 holders.
6. Securities Trading Policy.
7. A statement confirming the following.
 - a. Satisfaction of the conditions precedent and completion of the Acquisition Agreement between the Company and the Vendors including the issue of 320,000,000 Consideration Shares.
 - b. At least 120,000,000 ordinary shares and up to 160,000,000 ordinary shares at an issue price of \$0.025 per share pursuant to the Public Offer.



- c. 52,500,000 fully paid ordinary Conversion Shares to the Zelda Noteholders.
 - d. 16,000,000 fully paid ordinary Advisor Shares to CPS Capital Pty Ltd.
 - e. 40,000,000 Adviser and Employee Options with an exercise price of \$0.03125 and an expiry date that is five years from the date of issue.
 - f. The satisfaction of the conditions to the Public Offer, the close of the Public Offer, and the issue of all of the securities under the Public offer.
 - g. That there have been material subsequent events to alter the Company's consolidated statement of financial position as detailed in section 6 of the Prospectus.
 - h. That there are no legal, regulatory or contractual impediments to the Company undertaking the activities the subject of the commitments disclosed in the Prospectus.
 - i. The directors have obtained relevant legal opinions in respect of its proposed operations and are confident that there is no legal impediment (with reference to the Australian State and Commonwealth laws) to the Company carrying out its proposed operations.
 - j. The consultancy fee payable in accordance with the Biologica Consultancy Agreement (as set out at section 8.7 of the Prospectus) is \$10,000 (plus GST) per month.
 - k. That the Company is in compliance with the listing rules and in particular listing rule 3.1.
8. An updated statement of commitments and use of funds.
 9. An updated pro-forma statement of financial position based on actual funds raised.
 10. Audited accounts for Zelda Therapeutics Pty Ltd for the period ended 31 December 2015 and for the period ended 30 June 2016.

Security Code: ZLD

Dale Allen
Senior Adviser, Listings Compliance (Perth)